

Food & Function

Linking the chemistry and physics of food with health and nutrition

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: D. Gajic, T. Saksida, I. Koprivica, L. Senerovic, I. Mori, K. Katarina Savikin, N. Menkovic, N. Pejnovic and I. Stojanovi, *Food Funct.*, 2020, DOI: 10.1039/D0FO00946F.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

1 **Immunomodulatory activity and protective effects of chokeberry fruit extract on**
2 ***Listeria monocytogenes* infection in mice**

3

4

5 Dragica Gajić*^a, Tamara Saksida*^a, Ivan Koprivica^a, Lidija Šenerović^b, Ivana Morić^b,
6 Katarina Šavikin^c, Nebojša Menković^c, Nada Pejnović^a, Ivana Stojanović^{#a}

7 ^aDepartment of Immunology, Institute for Biological Research „Siniša Stanković“- National
8 Institute of Republic of Serbia, University of Belgrade, Bulevar despota Stefana 142, 11060
9 Belgrade, Serbia

10 ^bInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode
11 Stepe 444a , 11042 Belgrade 152 , Serbia

12 ^cInstitute for Medicinal Plants Research “Dr Josif Pančić”, Tadeuša Koščuška 1, 11000
13 Belgrade, Serbia

14

15

16 *equally contributed

17 #corresponding author

18 Ivana Stojanovic, PhD

19 Department of Immunology

20 Institute for Biological Research „Siniša Stanković“- National Institute of Republic of Serbia,

21 University of Belgrade

22 Bulevar despota Stefana 142

23 11060 Belgrade

24 Serbia

26 **Abstract**View Article Online
DOI: 10.1039/D0FO00946F

27 Chokeberry (*Aronia melanocarpa*) fruit extracts (CE) are rich in polyphenols and usually
28 exhibit immunomodulatory, anti-viral and anti-bacterial effects. We have previously shown
29 that the CE used in this study activated macrophages and stimulated effector T cell
30 differentiation *in vitro*. When applied orally to healthy mice, CE increased the proportion of
31 CD11c⁺ dendritic cells in the gut-associated lymphoid tissue. CE-pretreated BALB/c mice
32 readily eradicated orally ingested *Listeria monocytogenes* as evidenced by a slighter decrease
33 in body weight and number of bacteria recovered from the spleen and reduced spleen size
34 compared to the control infected mice. CE pretreatment in infected mice resulted in higher
35 proportions of CD11b⁺ macrophages and CD8⁺ cytotoxic T cells both in the gut and the
36 spleen. Phagocytosis, reactive oxygen species production and the proportions of activated
37 CD86⁺ macrophages (CD11b⁺) and dendritic cells (CD11c⁺) was also enhanced in CE-
38 pretreated infected mice. Further, the expression of inducible nitric oxide synthase and IL-6
39 was increased in CE-pretreated infected mice and the similar results were obtained in
40 peritoneal macrophages *in vitro*. This effect of CE was associated with increased
41 phosphorylation of I κ B and Notch1 production. Finally, CE pretreatment elevated the
42 proportion of perforin-producing cells in the spleen compared to control infected mice. This
43 study demonstrates that prophylactic treatment with CE leads to more rapid eradication of
44 bacterial infection with *L. monocytogenes* predominantly through increased activity of
45 myeloid cells in the gut and in the spleen.

- 47 Abbreviations
- 48 CE – Chokeberry extract
- 49 CFU – Colony-forming unit
- 50 DHR – Dihydrorhodamine 123
- 51 FCS – Fetal Calf Serum
- 52 FCS buffer – Flow Cytometry Staining buffer
- 53 GALT – Gut-associated lymphoid tissue
- 54 IFN- γ – Interferon- γ
- 55 IL-17 – Interleukin-17
- 56 IL-1 β – Interleukin-1 β
- 57 IL-6 – Interleukin-6
- 58 MLN – Mesenteric lymph nodes
- 59 NF- κ B – Nuclear factor κ B
- 60 NO – Nitric oxide
- 61 PBS – Phosphate-buffered saline
- 62 PP – Peyer's patches
- 63 ROS – Reactive oxygen species
- 64 TNF – Tumor necrosis factor

66 Introduction

View Article Online
DOI: 10.1039/D0FO00946F

67

68 Chokeberry (*Aronia melanocarpa*) fruit is characterized by high content of phenolic
69 constituents such as procyanidins, anthocyanins and phenolic acids known for their
70 antioxidative, anti-bacterial and immune-modulating properties.^{1,2} Therefore, chokeberry has
71 been traditionally used in the treatment of common cold.^{3,4,5} Chokeberry extracts have also
72 exhibited strong bacteriostatic and antiviral activity *in vitro*.⁶ In humans, the oral consumption
73 of chokeberry juice significantly reduced antibiotic intake in nursing home residents with
74 urinary infections.⁷ In addition, chokeberry was shown to exert beneficial effects in
75 cardiovascular diseases, diabetes, hypertension, hypercholesterolemia, indigestion and
76 malignant diseases.^{8,9}

77 Chokeberry may affect the functions of immune cells by exerting anti-inflammatory
78 effects or, in some conditions, stimulating immune reactions. Anti-inflammatory activities of
79 chokeberry in animal models of ulcerative colitis and neuroinflammation were mediated by
80 down-regulation of pro-inflammatory nitric oxide (NO) production, cyclooxygenase-2
81 expression and prostaglandin E2 production, along with reduction of interleukin-6 (IL-6) and
82 tumor necrosis factor (TNF).^{10,11,12,13} However, chokeberry extract was also shown to
83 stimulate NO secretion from macrophages and dendritic cells and stimulate T helper 1
84 lymphocyte differentiation, thus evidently exerting pro-inflammatory effects.¹⁴

85 *Listeria monocytogenes* is an opportunistic pathogen causing infection after ingestion
86 of contaminated food. Immunocompromised patients, neonates, pregnant women and elderly
87 persons may develop fatal complications such as meningitis or sepsis as a result of their
88 impaired cell-mediated immunity.¹⁵ In healthy people *L. monocytogenes* can cause acute, self-
89 limiting febrile gastroenteritis.¹⁶ Oral mouse models which mimic foodborne *L.*

90 *monocytogenes* infection are relevant for studying natural dissemination of bacteria from the View Article Online
DOI: 10.1039/D0FO00946F
91 gut to the spleen, liver, and brain.¹⁷

92 Pathogen-associated molecular patterns from *L. monocytogenes* engage pattern
93 recognition receptors on epithelial cells, macrophages and dendritic cells in the gut mucosa
94 and trigger intracellular signaling pathways (e.g. the nuclear factor κ B - NF- κ B pathway and
95 others) that lead to the activation of both the innate and adaptive arm of the immune
96 response.¹⁵ Cells of the innate immunity eliminate *L. monocytogenes* by producing reactive
97 oxygen species (ROS) and NO that are toxic to bacteria and by serving as antigen-presenting
98 cells that activate the cells of adaptive immunity. This is achieved through the up-regulation
99 of co-stimulatory molecules on antigen-presenting cells, such as CD80, CD86 and CD40.¹⁸
100 Additionally, these cells produce pro-inflammatory cytokines, interleukin-1 β (IL-1 β) and
101 interleukin-18 that promote the development of the adaptive immune response.¹⁹ *L.*
102 *monocytogenes* induces a strong type 1 immune response in which interferon- γ (IFN- γ), a
103 cytokine generally essential for host resistance to intracellular bacteria, has a key role.
104 Activated CD8⁺ cells are involved in *L. monocytogenes* clearance by both mechanisms of
105 direct bacteria killing via perforin and granzymes and by IFN- γ production.²⁰

106 We have previously shown that 7-day long oral application of chokeberry extract (CE)
107 changed the frequencies of immune cells within the intestine in healthy C57BL/6 mice.¹⁴ So
108 far, there are no data whether these CE-mediated immunoregulatory effects could aid the
109 immune response against bacterial infection. Therefore, the objective of this study was to
110 delineate the effects of CE on the immune response in the gut-associated lymphoid tissue
111 (GALT) and spleen before and after the infection with *Listeria monocytogenes* in BALB/c
112 mice. Also, we aimed to determine the potential molecular mechanisms underlying CE effects
113 on the anti-bacterial immune response *in vivo* and *in vitro*.

114

115 **Material and methods**

View Article Online
DOI: 10.1039/D0FO00946F

116

117 **Chokeberry extract preparation**

118 In this work, we used an extract that we produced in our previous study.¹⁴ Briefly, chokeberry
119 was provided by Conimex Trade Ltd. from the organic cultivation field, immediately dried at
120 40°C for 48 h and grinded by a laboratory mill. Grinded material was extracted using 50%
121 ethanol and after ethanol evaporation under vacuum, water residue was freeze-dried.^{21,Error!}
122 **Bookmark not defined.** Chokeberry extract (CE) contained cyanidin-3-galactoside (0.34 mg/g),
123 cyanidin-3-arabinoside (0.16 mg/g), cyanidin-3-glucoside (0.06 mg/g), quercetin-3-glucoside
124 (0.15 mg/g), quercetin-3-galactoside (0.31 mg/g), quercetin-3-rutinoside (0.28 mg/g),
125 chlorogenic acid (3.53 mg/g) and proanthocyanidins (36.5 mg CE/g in total).¹⁴ Moreover, CE
126 was free of viable bacteria (tested in the Brain Heart Infusion broth), and no endotoxin was
127 detected (tested by PYROGENT™-5000 Kinetic Turbidimetric LAL Assay, Lonza
128 Netherlands B.V., Geleen, The Netherlands).

129 **Preparation of *L. monocytogenes* for infection**

130 Bacteria were grown in BHI broth at 37°C on a rotary shaker at 180 rpm. After 20 h, bacteria
131 were diluted 50 times in BHI broth and cultured until mid-log-phase growth was reached. The
132 optical density of the bacterial suspension was read with a spectrophotometer, and the
133 numbers of *L. monocytogenes* CFU were extrapolated from a standard growth curve. To
134 prepare the inoculum for the mice infection, appropriate dilutions were made in sterile
135 phosphate-buffered saline (PBS) to achieve the desired bacterial concentration (5.5×10^7
136 cell/ml). The actual number of CFU in the inoculum was verified by plating on BHI agar.

137

138 **Mice**

139 BALB/c mice were bred and kept under standard conditions with free access to standard
140 pelleted diet and tap water at the Animal Facility of the Institute for Biological Research
141 "Siniša Stanković"- National Institute of Republic of Serbia, University of Belgrade. All
142 experiments, approved by the Ethical Committee of the Institute for Biological Research
143 "Siniša Stanković" (App.No 02-5/19-01-1036), were in accordance with the Directive
144 2010/63/EU and complied with the ARRIVE guidelines.

145 **CE pretreatment and infection with *L. monocytogenes***

146 Two months old male BALB/c mice were separated into four groups in a blind fashion. The
147 first group received 100 µl of water for 7 days by oral gavage (control group for CE - 6 mice).
148 The second group orally received 100 µl of CE (50 mg/kg bw) for 7 days (6 mice). The third
149 group received 100 µl of water for 7 days by oral gavage and on the 8th day was orally
150 infected with *L. monocytogenes* (5×10^6 CFU in 100 µl of PBS – 18 mice). The fourth group
151 was treated orally every day with 100 µl of CE (50 mg/kg bw) for 7 days and on the 8th day
152 infected with *L. monocytogenes* (5×10^6 CFU in 100 µl of PBS - 18 mice). The animals were
153 euthanized by CO₂ asphyxiation. The *ex vivo* analysis of immune cells for the first and the
154 second group was performed 24 h after the final treatment with either CE or water, while for
155 the third and the fourth group it was performed 48 h after the infection with *L.*
156 *monocytogenes*. The third and the fourth group consisted of 18 mice, 6 for *ex vivo* analysis
157 and an additional 12 mice were used for the monitoring of body mass and animal appearance
158 up to 7 days after the infection and the initial (preliminary) analysis of splenic bacterial
159 burden 48 h after the infection. Body weight gain in % was determined by the following
160 formula $100 - (X_{\text{current}} - X_0) * 100$, where X_{current} is the measured weight of the mouse on the
161 specific day (precision scales PCE-DS600, PCE Group, Meschede, Germany) and X_0 the
162 body weight of the mouse at the beginning of the experiments.

163 **Recovery of *L. monocytogenes* from the tissues of infected mice**

View Article Online
DOI: 10.1039/D0FO00946F

164 The spleen was removed aseptically from infected mice 48 h after the infection. The weight of
165 the spleens was determined using precision scale (Mettler AE 200, Mettler-Toledo GmbH,
166 Giessen, Germany) and the spleens were homogenized in sterile PBS. Two-fold dilutions
167 were prepared and plated in triplicate on BHI agar. The plates were incubated at 37°C for 24 h
168 and the colonies were counted. The data were expressed as the mean \pm standard deviation of
169 *L. monocytogenes* CFU per gram of tissue (wet weight).

170

171 **Immune cell isolation**

172 Spleen, mesenteric lymph nodes (MLN) and small intestines were collected 48 h after the
173 infection. Spleens were passed through a cell strainer with pores of 40 μ m. RBC Lysis Buffer
174 (eBioscience, San Diego, CA, USA) was used in order to remove red blood cells, and after the
175 reaction was stopped with PBS 3% Fetal Calf Serum (FCS - Sigma-Aldrich, St. Louis, MO,
176 USA) and centrifugation, spleen cells were counted and prepared for further manipulation.
177 Peyer's patches (PP) were excised from the small intestine and PP cells as well as MLN cells
178 were obtained after passage through a 40 μ m cell strainer. Cells were counted on LUNA-II™
179 Automated Cell Counter (Logos Biosystems, Gyeonggi-do, Korea) and used for further
180 analysis. Peritoneal cells from healthy BALB/c mice were collected by injecting cold PBS
181 and recovering the fluid from the peritoneum using a pipette. Cells were centrifuged at 500 g,
182 resuspended in RPMI medium supplemented with 5% FCS, 1% penicillin and streptomycin,
183 0.02 mM Na-pyruvate, 25 mM HEPES, and 2 mM L-glutamine (Sigma-Aldrich), counted and
184 2.5×10^6 cells were placed in 24-well adherent cell plates (Sarstedt, Numbrecht, Germany).
185 After 2 h incubation at 37°C, cells were rinsed with warm PBS twice and the remaining
186 adherent cells were predominantly macrophages. CE (25 μ g/ml) was added and NO

187 production was measured and protein or mRNA isolation was performed after 24 h of
188 incubation.

189 **Flow cytometry**

190 Viable spleen, MLN and PP cells were stained for detection of surface molecules. The
191 following anti-mouse antibodies were used: CD4-FITC (rat IgG2b, κ), CD8-PE-Cy5.5 (rat
192 IgG2a, κ), CD11b-FITC (rat IgG2b, κ), CD11c-PE-Cy5.5 (Armenian hamster IgG), CD11c-
193 FITC (Armenian hamster IgG) and CD86-PE-Cy5.5 (rat IgG2a, κ) (all from ThermoFisher
194 Scientific, Waltham, MA, USA). The staining was performed for 45 min at 4°C, with the
195 antibodies dissolved in Flow Cytometry Staining buffer (FCS buffer, eBioscience). The
196 samples were washed twice and resuspended in FCS buffer for analysis. For intracellular
197 staining, cells were stimulated for 4 h with Cell Stimulation Cocktail (1:500, eBioscience) and
198 stained for extracellular markers as described. Cells were then fixed in 2% paraformaldehyde,
199 permeabilized with permeabilization buffer (PB, eBioscience), after which the following anti-
200 mouse antibodies were used: IFN- γ -PerCP-Cy5.5 (rat IgG1, κ), Granzyme B-FITC (rat
201 IgG2a, κ), IL-17-PE (rat IgG2a) (all from Thermo Fisher Scientific). Staining was performed
202 for 45 min at 4°C, washed once with PB, once with PBS and finally resuspended in FCS
203 buffer. For Perforin-PE (rat IgG2a, κ , eBioscience) staining, the FoxP3 permeabilization
204 protocol was used, according to the manufacturer's instructions. Cells were detected by Partec
205 CyFlow Space and analysed by FlowMax software (Partec, Görlitz, Germany). In all
206 experiments isotype-matched controls (eBioscience) were included.

207 **Phagocytosis assay**

208 PP and spleen cells were incubated for 1 h at 37°C in 24-well plate (1×10^5 cells/well) and the
209 nonadherent cells were then washed away with PBS. PE-labelled amine-modified polystyrene
210 latex beads (mean particle size 1 μ m, Sigma-Aldrich) were pre-opsonised in PBS 50% FCS

211 for 1 h at 37°C and then incubated with adhered PP and spleen cells for 1 h at 37°C (10 beads/cell). After washing, cells were resuspended in FCS buffer and the proportion of
212 phagocytic cells and phagocytic activity were analyzed with flow cytometry.
213

214 **Measurement of reactive oxygen species**

215 Immediately after isolation, PP and spleen cells (5×10^5) were exposed to 5 μM
216 dihydrorhodamine 123 (DHR) (Sigma-Aldrich) for 20 min at 37°C. Cells were then washed
217 with PBS and finally resuspended in FCS buffer. The proportion of reactive oxygen species
218 (ROS)-producing cells and a measure of intracellular production of ROS were detected by
219 flow cytometry.

220 **NO secretion**

221 Peritoneal macrophages (2×10^5) were cultured in 96-well plates and treated with CE (25
222 $\mu\text{g/ml}$) for 24 h. Nitrite accumulation, an indicator of NO production, was measured in cell-
223 culture supernatants using the Griess reagent.¹⁴

224 **Immunoblot**

225 *In vitro* cultured peritoneal cells (2.5×10^6) or *ex vivo* isolated spleen cells were lysed with a
226 buffer containing 62.5 mM Tris-HCl (pH 6.8), 2% SDS, 50 mM DTT, 10% glycerol, with the
227 Protease Inhibitor Cocktail (all from Sigma-Aldrich). All samples were boiled with the 4 \times
228 SDS sample loading buffer. Sample electrophoresis was performed on 12% SDS-
229 polyacrylamide gel. By using a semi-dry blotting system (Semi-Dry Transfer Unit, GE
230 Healthcare, Buckinghamshire, England), the protein samples were electro-transferred from
231 the gel onto polyvinylidene difluoride membranes. The membranes were then blocked with
232 PBST (PBS 0.1% Tween-20, Sigma-Aldrich) containing 5% BSA and probed with specific
233 antibodies diluted in PBST 1% BSA, according to the manufacturer's instructions. The
234 following primary antibodies were used: rabbit anti-mouse phospho-I κ B (1:1000, Sigma-

235 Aldrich) rabbit anti-mouse I κ B (1:1000, Cell Signalling Technology, Danvers, MA, USA),
236 rabbit anti-mouse Notch1 (1:300, Sigma-Aldrich) and mouse anti-mouse β -actin (1:1000,
237 Sigma-Aldrich). Appropriate HRP conjugated secondary antibodies were used: anti-rabbit
238 IgG (1:5000, Invitrogen, Carlsbad, CA, USA) or anti-mouse IgG (1:5,000, Invitrogen).
239 Detection was achieved with Immobilon Western Chemiluminescent HRP Substrate
240 (Millipore, Billerica, MA, USA), and the signal was captured with X-ray film (Kodak,
241 Rochester, NY, USA). Densitometry was performed with Fiji, an open-source software for
242 biological image analysis, and the production of specific proteins was presented relative to the
243 production of either their non-phosphorylated protein forms or of β -actin.

244 **Reverse transcription and real-time PCR**

245 TriReagent (Metabion, Martinsried, Germany) was used for dissolving the samples and
246 centrifugation with chloroform at 12000 g was performed subsequently. After RNA isolation
247 from the aqueous layer and precipitation with isopropanol, reverse transcription was
248 performed. Samples (1 μ g) were incubated with random hexamer primers and RevertAid™
249 M-MuLV Reverse Transcriptase (Fermentas, Vilnius, Lithuania). Target sequences of cDNA
250 were amplified using SYBRGreen PCR master mix (Applied Biosystems, Woolston, UK) in
251 Real-time PCR machine (Applied Biosystems). Primer pairs for iNOS were: forward 5'-CTG
252 CAG CAC TTG GAT CAG GA-3' and reverse 5'-GCC AGA AAC TTC GGA AGG GA-3'
253 (NM_001313922.1), TNF forward 5'-CCACGTCGTAGCAAACCAC-3' and reverse 5'-
254 TGGGTGAGGAGC ACGTAGT-3' (NM_013693.3), for IL-1 β forward 5'-
255 GCTGAAAGCTCTCCACCTCAA-3' and reverse 5'- TGTCGTTGCTTGGTTCTCCTTG-3'
256 (NM_008361.4), for IL-6 forward 5'-TTG CCT TCT TGG GAC TGA TGC T-3' and reverse
257 5'-GTA TCT CTC TGA AGG ACT CTG G-3' (NM_031168.2), and for β -actin they were 5'-
258 GACCTGACAGACTACC-3' and 5'-GGCATAGAGGTCTTTACGG-3' (NM_007393.2).
259 Gene expression was determined as $2^{-(Ct-Ca)}$, where Ct is target gene cycle threshold and Ca is

260 β -actin cycle threshold. SDS2.1 software (Applied Biosystems) was used to analyse the
261 obtained cycle thresholds.

262 **Statistical Analysis**

263 Data are presented as mean \pm SD. A two tailed Student's t test was used for determination of
264 significance of differences between experimental groups, or a Mann-Whitney non-parametric
265 test for the analysis of the data that were not normally distributed. If $p < 0.05$, the differences
266 were considered as statistically significant. Statistical analyses were performed using
267 GraphPad Prism 8 software (GraphPad Software, Inc., La Jolla, CA, USA).

268

270 **Results**

271 **Pretreatment with chokeberry extract accelerates eradication of *L. monocytogenes*** 272 **infection in BALB/c mice**

273 BALB/c mice were treated with CE or vehicle for 7 days orally and then infected with *L.*
274 *monocytogenes* through the oral route. The results showed that after the infection, the control
275 mice which received water instead of CE during pretreatment exhibited significant weight
276 loss (Fig. 1A). In contrast, body weight of CE-pretreated mice did not significantly change
277 compared to their weight on day 0. This is concordant with the number of CFU found in the
278 spleen two days after the infection; CE-pretreated mice had significantly lower bacterial
279 burden in the spleen compared to the vehicle-pretreated mice (Fig. 1B). Also, the relative
280 spleen weight was higher in the infected control mice (Fig. 1C).

281

282 **The effect of CE pretreatment on immune cells in the GALT**

283 The more successful eradication of *L. monocytogenes* observed in the CE-pretreated mice
284 might be the consequence of altered immune response within GALT that includes PP and
285 MLN. Therefore, we compared the immune cell composition in PP of vehicle and CE-treated
286 mice with or without infection. Results showed that CE treatment in non-infected animals did
287 not change the proportions of CD11b⁺ macrophages, CD8⁺ cytotoxic T lymphocytes and
288 CD4⁺ T helper lymphocytes while it significantly increased the proportion of CD11c⁺
289 dendritic cells (Table 1). After the infection, CE-pretreated mice had significantly increased
290 proportions of CD11b⁺ (Fig. 2A) and CD8⁺ (Fig. 2C) cells compared to the control infected
291 mice, while CD11c⁺ (Fig. 2B) and CD4⁺ (Fig. 2D) cell proportions remained the same.

292

293 **The effect of CE pretreatment on immune cells in the spleen**

View Article Online
DOI: 10.1039/D0FO00946F

294 Lower bacterial burden found in the spleen of CE-treated animals prompted us to investigate
295 the effect of CE on cells important for bacterial clearance. CE pretreatment did not change the
296 proportions of splenic macrophages (CD11b⁺), dendritic cells (CD11c⁺) or CD8⁺
297 lymphocytes, while the proportion of CD4⁺ lymphocytes was down-regulated (Table 1)
298 compared to the untreated animals (before the infection). Importantly, after the infection, in
299 CE-pretreated animals the proportion of macrophages (Fig. 3A) and CD8⁺ lymphocytes (Fig.
300 3C) were up-regulated. However, the proportion of CD11c⁺ dendritic cells in spleens of
301 infected CE-pretreated mice was lower compared to control infected mice (Fig. 3B), while the
302 proportion CD4⁺ (Fig. 3D) remained the same.

303

304 **The effect of CE on myeloid cells - mechanism of action**

305 Next, we wanted to examine the possible mechanism of action of CE pretreatment on
306 bacterial infection and therefore we investigated the activities of macrophages and dendritic
307 cells. CE pretreatment increased both the proportion of actively phagocytic cells within the PP
308 (Fig. 4A) and their phagocytic activity in the PP and spleen (Fig. 4A, C), determined by mean
309 fluorescence intensity of ingested fluorescent latex beads. Further, the proportion of cells that
310 produced ROS was higher in PP of CE-pretreated infected animals compared to infected
311 controls (Fig. 4B). ROS-producing cells proportion and ROS production in the spleen was the
312 same between the treatment groups (Fig. 4D). The higher expression of the co-stimulatory
313 molecule CD86 on myeloid cells coincided with their increased activity. We found that CE
314 pretreatment up-regulated the proportion of macrophages that express CD86 in PP (Fig. 5A)
315 and spleen (Fig. 5B) and the proportions of macrophages and dendritic cells expressing CD86
316 in MLN (Fig. 5C). In addition, spleen cells obtained from CE-pretreated infected mice

317 expressed higher levels of iNOS (Fig. 6A) and IL-6 mRNA (Fig. 6B) compared to the cells of
318 infected control mice. IL-1 β expression remained similar between the groups (0.19 \pm 0.09 vs
319 0.10 \pm 0.01, p=0.387, infection vs CE+infection) as well as TNF expression (0.037 \pm 0.015 vs
320 0.022 \pm 0.009, p=0.652, infection vs CE+infection). *In vitro* studies on peritoneal macrophages
321 isolated from BALB/c mice showed a significant stimulation of NO production after CE
322 treatment (25 μ g/ml) (Fig. 6C), accompanied by the increase in iNOS (Fig. 6D) and IL-6
323 mRNA (Fig. 6E) and comparable levels of IL-1 β mRNA (0.479 \pm 0.393 vs 0.323 \pm 0.238,
324 p=0.677, infection vs CE+infection) and TNF (0.057 \pm 0.048 vs 0.249 \pm 0.142, p=0.091,
325 infection vs CE+infection).

326 In order to investigate the CE effect on signaling pathways involved in iNOS and IL-6
327 expression, we measured the activation of NF- κ B through I κ B phosphorylation and Notch1
328 protein expression in macrophages *in vitro*. Results indicate that CE activated NF- κ B (Fig.
329 6F) and induced Notch1 expression (Fig. 6G) in macrophages 24 h after the treatment.

330

331 **The effect of CE pretreatment on CD8⁺ T cell-derived cytotoxic proteins**

332 The eradication of intracellular bacteria depends upon cytotoxic mediators such as perforin,
333 granzyme and IFN- γ , a cytokine that drives anti-bacterial immune response. CE-pretreated
334 infected mice exhibited similar proportions of cells that produced perforin, granzyme and pro-
335 inflammatory cytokine IFN- γ or interleukin 17 (IL-17) at intestinal draining sites, PP and
336 MLN (Table 2). The effect of CE was only observed in the increased proportion of perforin⁺
337 cells in the spleen (Table 2).

338

339

340 **Discussion**View Article Online
DOI: 10.1039/D0FO00946F

341 This study shows that CE pretreatment results in faster eradication of *L. monocytogenes*
342 infection. In this study CE application was ceased one day prior to infection, making the
343 direct anti-bacterial effect not probable, but reliant on the modulation of immune response.
344 CE effect was predominantly mediated by the increased phagocytic ability of macrophages
345 and bacterial destruction through NO and ROS production. Furthermore, the increased
346 expression of the co-stimulatory molecule CD86 on myeloid cells (macrophages and
347 dendritic cells) and IL-6 was associated with enhanced activation of the adaptive immunity,
348 predominantly CD8⁺ cytotoxic T cells. Comparable results were observed *in vitro* where CE
349 significantly up-regulated iNOS and IL-6 expression and NO production in peritoneal
350 macrophages, further supporting the conclusions from the *in vivo* model. The stimulatory
351 effect of CE on macrophage was probably mediated by the activation of NF- κ B transcription
352 factor and Notch1 transcription regulator.

353 Orally ingested *L. monocytogenes* enters the mucosa of the intestinal tract via enterocytes or
354 indirectly through invasion of Peyer's patches and then disseminates to the spleen, liver and
355 brain.^{15,17} The ability of myeloid cells to phagocytize bacteria is of great importance for
356 successful eradication of bacteria.¹⁵ The faster elimination of *L. monocytogenes* observed in
357 CE-pretreated mice was most probably a result of CE-mediated changes in the immune
358 system before the infection. The most evident changes were observed in the gut immune
359 system where CE increased the proportion of dendritic cells and, after the infection, the
360 phagocytic ability of myeloid cells. This CE effect is similar to the activity of a protein
361 fraction from garlic which was shown to augment *in vitro* macrophage cytotoxicity and
362 phagocytosis and activate macrophages to stimulate lymphocyte proliferation.²² Flavonoid
363 constituents of CE such as quercetin could be responsible for the stronger induction of

364 phagocytosis observed in CE-pretreated mice or in macrophages *in vitro*.^{14,23} As quercetin is
365 identified as an mTORC1 inhibitor²⁴ and mTORC1 suppression is associated with increased
366 macrophage pro-inflammatory status,^{25,26} the observed activation of myeloid cells may be
367 mediated by quercetin-directed mTORC1 inhibition. Enhanced phagocytosis is probably one
368 of the reasons for lower number of bacteria recovered from the spleen of CE-pretreated mice.

369 After ingestion of bacteria, myeloid cells produce NO and ROS that mediate bacterial
370 killing.²⁷ Although CE contains high levels of polyphenols (chlorogenic acid,
371 proanthocyanidins) which generally exhibit anti-oxidant activity and decrease NO,^{28,29} our
372 study has shown that CE significantly increased NO production in macrophages *in vitro* and
373 iNOS expression in splenocytes *in vivo*. The observed stimulatory effect on NO production is
374 similar to the studies that tested an ethanol fraction of chokeberry on endothelial cells *in*
375 *vitro*³⁰ or its juice *in vivo*.³¹ The stimulatory effect on NO is not solely a feature of CE. There
376 is also evidence of macrophage activation by other plant crude extract applications. For
377 example, hot water extract of *Herba pogostemonis* elicited altered morphology and elevated
378 iNOS mRNA in macrophages *in vitro* and thereby protected mice against *Salmonella*
379 *typhimurium*-induced liver damage and mortality.³² Additionally, *Echinacea purpurea*
380 extract was shown to activate the innate immune response, stimulating the production of IL-
381 6, TNF, IL-12, and NO from macrophages *in vitro*.³³ Specific flavonoid compounds,
382 proanthocyanidins for example, have been shown to induce moderate levels of NO in
383 macrophages.³⁴ Also, they have stimulated NO production in endothelial cells.³⁵ The effect
384 of quercetin on NO was more thoroughly investigated, showing that it can induce NO
385 production and increase NO longevity through suppression of ROS generating enzymes and
386 subsequent reduction of superoxide and peroxynitrite which neutralize NO.³⁶ However, the
387 observed increased ROS production after CE application suggested that this cannot be the
388 mechanism of NO up-regulation. According to our results, CE influenced signaling pathways

389 responsible for NO generation, i.e. it enhanced the activation of iNOS mandatory
390 transcription factor NF- κ B³⁷ and subsequently stimulated iNOS mRNA expression.

391 Along with increased ROS and NO, the CE extract stimulated IL-6 expression both *in vitro*
392 and *in vivo*. IL-6 can be regulated either by canonical NF- κ B pathway alone³⁸ or in
393 combination with Notch1, a protein that enables deactivation of specific repressors of RNA
394 transcription.^{39,40} Therefore, the observed increase in NF- κ B and Notch1 in macrophages
395 upon CE treatment was most likely responsible for the up-regulated IL-6 mRNA expression.

396 After myeloid cell-mediated digestion of bacteria, the myeloid cells commonly up-regulate
397 their co-stimulatory molecules CD80, CD86 or CD40, which mediate the activation of
398 adaptive immune cells.²⁷ In concordance with the previous findings that CE stimulated CD86
399 expression in macrophages *in vitro*,¹⁴ CE-pretreated mice up-regulated the expression of
400 CD86 on dendritic cells and macrophages in the gut, MLN and spleen. Increased CD86 could
401 be responsible for the observed IL-6 up-regulation as it has been previously shown that CD86
402 crosslinking stimulate IL-6 in dendritic cells through NF- κ B and Notch1 signaling.⁴¹ The
403 observed increase of CD86 on macrophages and dendritic cells was associated with the
404 increase of CD8⁺ T cell proportions. However, only perforin-secreting cells which mediate
405 direct bacterial killing²⁸ were found to be increased in spleens of CE-pretreated and infected
406 mice, while the proportions of cells producing other pro-inflammatory mediators such as
407 IFN- γ , IL-17 or granzyme B were unchanged between the groups. This suggests that the
408 increased CD8⁺ proportions accomplished a more efficient *L. monocytogenes* clearance. This
409 is in contrast with, for example, a garlic extract that stimulated IFN- γ -producing cells *in vivo*
410 in the presence of *Mycobacterium tuberculosis*, while no changes were observed in the
411 proportion of macrophages, dendritic cells, CD4⁺ and CD8⁺ lymphocytes.⁴²

412 **Conclusions**

413 Since the bacterial resistance to commonly used antibiotics is increasing worldwide, the wide
414 spectra of antimicrobial research are geared towards the discovery and development of novel
415 agents that would preferably stimulate the anti-bacterial immune response. This study
416 demonstrates the immunostimulatory effects of CE. Prophylactic treatment with CE resulted
417 in enhanced eradication of *L. monocytogenes* in mice. Mechanisms of CE action include the
418 activation and enhanced function of gut-associated myeloid cells relevant in the fight against
419 *L. monocytogenes* infection and increased CD8⁺ T and perforin-producing cells in spleen.
420 Further investigation on the determination of the relevant constituent from CE that promotes
421 this activity will be performed in the future.

422 **Authors' contribution**

423 IS designed the experiments, analyzed data and wrote the manuscript, DG and TS performed
424 *in vivo* and *ex vivo* experiments and analyzed data, IK and NP performed *ex vivo*
425 experiments, KS and NM provided the extract, LS and IM provided the bacteria and
426 performed *ex vivo* measurement of *L. monocytogenes* CFU from the spleen homogenate. All
427 authors proofread the manuscript and approved the submission.

428 **Conflicts of interest**

429 The authors have declared no conflicts of interest.

430 **Acknowledgements**

431 This work was supported by Ministry of Education, Science and Technological Development
432 of Republic of Serbia (grants: #451-03-68/2020-14/200007, 451-03-68/2020-14/200003,
433 451-03-68/2020-14/200042).

435 **Figure legends**View Article Online
DOI: 10.1039/D0FO00946F436 **Figure 1. The effect of CE pretreatment on *L. monocytogenes* infection in BALB/c mice.**

437 (A) Body weight change (%) during the days post infection in CE- and control-pretreated
438 infected mice. The total number of mice per group was 8. (B) Bacterial burden in the spleen,
439 observed through the number of colony forming units (CFU), and relative spleen weight (C),
440 measured 48 h after the infection. The experiment was performed twice and the results of both
441 experiments are shown. The total number of mice per group was from 10 to 12. * $p < 0.05$
442 represents a statistically significant difference vs. the control infection group.

443 **Figure 2. The effect of CE pretreatment on immune cells in the GALT.** The proportion of

444 immune cells was determined in PP of infected and CE-treated infected mice with *L.*
445 *monocytogenes* 48 h after the infection. The following immune cells were analyzed by flow
446 cytometry: (A) CD11b⁺ macrophages, (B) CD11c⁺ dendritic cells, (C) CD8⁺ cytotoxic T
447 lymphocytes and (D) CD4⁺ T helper cells. Representative dot plots are shown below the
448 graphs. *Ex vivo* experiments were performed on 6 mice per group. Values of p are given
449 where significant differences were found.

450 **Figure 3. The effect of CE pretreatment on immune cells in the spleen.** The immune cell

451 proportion was observed in the spleen of infected and CE-treated infected mice with *L.*
452 *monocytogenes* 48 h after infection. The following immune cells were analyzed by flow
453 cytometry: (A) CD11b⁺ macrophages, (B) CD11c⁺ dendritic cells, (C) CD8⁺ cytotoxic T
454 lymphocytes and (D) CD4⁺ T helper cells. Representative dot plots are shown on the right-
455 hand side. *Ex vivo* experiments were performed on 6 mice per group. Values of p are given
456 where significant differences were found.

457 **Figure 4. CE pretreatment effect on phagocytosis and ROS production.** The proportion of

458 phagocytic cells (%) and phagocytic activity, shown through the mean fluorescence intensity

459 (MFI), were analyzed in the Peyer's patches (A) and the spleens (C) of CE or vehicle
460 pretreated infected mice two days after *L. monocytogenes* infection. The proportion of ROS-
461 producing cells and their MFI in Payer's patches (B) and spleens (D) of CE or vehicle
462 pretreated infected mice two days after *L. monocytogenes* infection. Representative dot plots
463 are shown on the right-hand side. *Ex vivo* experiments were performed on 6 mice per group.
464 Values of *p* are given where significant differences were found.

465 **Figure 5. CE pretreatment effect on expression of myeloid cells co-stimulatory**
466 **molecules.** The proportion (%) of CD86 expressing macrophages (CD86⁺CD11b⁺ cells) and
467 dendritic cells (CD86⁺CD11c⁺ cells) was determined in the PP (A), spleen (B) and MLN (C)
468 of infected mice and CE-pretreated and infected mice 48 h after the infection. Representative
469 dot plots are shown on the right-hand side. *Ex vivo* experiments were performed on 6 mice per
470 group. Values of *p* are given where significant differences were found.

471 **Figure 6. CE effect on expression of pro-inflammatory mediators and transcription**
472 **regulators.** iNOS mRNA expression (A) and IL-6 mRNA expression (B) was determined in
473 spleen cells of infected and CE-pretreated and infected mice 48 h after the infection with *L.*
474 *monocytogenes*. *Ex vivo* experiments were performed on 6 mice per group. Peritoneal
475 macrophages were *in vitro* treated with CE (25 µg/ml) and 24 h after the treatment NO
476 production (C), iNOS expression (D) and IL-6 expression (E) were determined by RT-PCR.
477 The level of IκB phosphorylation (pIκB) was normalized to total IκB production in
478 macrophages (F), while Notch1 production was normalized to the level of β-actin (determined
479 by western blot) (G). Appropriate membrane images are presented. The experiment was
480 performed in quadruplets. Values of *p* are given where significant differences were found.

482 **References**View Article Online
DOI: 10.1039/D0FO00946F

- ¹M.P. Kähkönen, A.I. Hopia and M. Heinonen, Berry phenolics and their antioxidant activity, *J Agric Food Chem*, 2001, **49**, 4076–4082.
- ²X. Wu, L. Gu, R.L. Prior and S. McKay, Characterization of anthocyanins and proanthocyanins in some cultivars of *Ribes*, *Aronia*, and *Sambucus* and their antioxidant capacity, *J Agric Food Chem*, 2004, **52**, 7846–7856.
- ³P. Denev, M. Číž, M. Kratchanova and D. Blazheva, Black chokeberry (*Aronia melanocarpa*) polyphenols reveal different antioxidant, antimicrobial and neutrophil-modulating activities, *Food Chem.*, 2019, **284**, 108–117.
- ⁴T. Jurikova, J. Mlcek, S. Skrovankova, D. Sumczynski, J. Sochor, I. Hlavacova, L. Snopek and J. Orsavova, Fruits of Black Chokeberry *Aronia melanocarpa* in the Prevention of Chronic Diseases, *Molecules*, 2017, **22**, 944.
- ⁵I. Banjari, A. Misir, K. Šavikin, S. Jokić, M. Molnar, H.K.S. De Zoysa and V.Y. Waisundara, Antidiabetic Effects of *Aronia melanocarpa* and Its Other Therapeutic Properties, *Front Nutr*, 2017, **4**, 53.
- ⁶S.V. Valcheva-Kuzmanova and A. Belcheva, Current knowledge of *Aronia melanocarpa* as a medicinal plant, *Folia Med (Plovdiv)*, 2006, **48**, 11–17.
- ⁷M. Handeland, N. Grude, T. Torp and R. Slimestad, Black chokeberry juice (*Aronia melanocarpa*) reduces incidences of urinary tract infection among nursing home residents in the long term--a pilot study, *Nutr Res*, 2014, **34**, 518–525.
- ⁸A. Kokotkiewicz, Z. Jaremicz and M. Luczkiewicz, *Aronia* plants: a review of traditional use, biological activities, and perspectives for modern medicine, *J Med Food.*, 2010, **13**, 255–269.
- ⁹N. Čujić, K. Šavikin, Z. Miloradović, M. Ivanov, U.J. Vajić, D. Karanović, J. Grujić-Milanović, D. Jovović and N. Mihailović-Stanojević, Characterization of dried chokeberry fruit extract and its chronic effects on blood pressure and oxidative stress in spontaneously hypertensive rats, *J Funct Foods*, 2018, **44**, 330–339.
- ¹⁰S.H. Kang, Y.D. Jeon, K.H. Moon, J.H. Lee, D.G. Kim, W. Kim, H. Myung, J.S. Kim, H.J. Kim, K.S. Bang and J.S. Jin, *Aronia* Berry Extract Ameliorates the Severity of Dextran Sodium Sulfate-Induced Ulcerative Colitis in Mice, *J Med Food*, 2017, **20**, 667–675.

¹¹D.C. Montrose, N.A. Horelik, J.P. Madigan, G.D. Stoner, L.S. Wang, R.S. Bruno, H.J. Park, C. Giardina and D.W. Rosenberg, Anti-inflammatory effects of freeze-dried black raspberry powder in ulcerative colitis, *Carcinogenesis*, 2011, **32**, 343-50.

¹²D.A. Martin, R. Taheri, M.H. Brand, A. Draghi, F.A. Sylvester and B.W. Bolling, Anti-inflammatory activity of Aronia berry extracts in murine splenocytes, *J Funct Foods*, 2014, **8**, 68–75.

¹³K.P. Lee, N.H. Choi, H.S. Kim, S. Ahn, I.S. Park and D.W. Lee, Anti-neuroinflammatory effects of ethanolic extract of black chokeberry (*Aronia melanocarpa* L.) in lipopolysaccharide-stimulated BV2 cells and ICR mice, *Nutr Res Pract*, 2018, **12**, 13-19.

¹⁴D. Gajic, T. Saksida, I. Koprivica, M. Vujicic, S. Despotovic, K. Savikin, T. Jankovic and I. Stojanovic, Chokeberry (*Aronia melanocarpa*) fruit extract modulates immune response *in vivo* and *in vitro*, *J Funct Foods*, 2020, **66**, 103836.

¹⁵M. Schuppler and M.J. Loessner, The Opportunistic Pathogen *Listeria monocytogenes*: Pathogenicity and Interaction with the Mucosal Immune System, *Int J Inflam*, **2010**, 704321.

¹⁶S.T. Ooi and B. Lorber, Gastroenteritis due to *Listeria monocytogenes*, *Clin Infect Dis*, 2005, **40**, 1327-1332.

¹⁷M.G. Pitts and S.E.F. D'Orazio, A Comparison of Oral and Intravenous Mouse Models of Listeriosis, *Pathogens*, 2018, **7**.

¹⁸D.S. Damlund, L. Christophersen, P.Ø. Jensen, M. Alhede, N. Høiby and C. Moser, Activation of pulmonary and lymph node dendritic cells during chronic *Pseudomonas aeruginosa* lung infection in mice, *APMIS*, 2016, **124**, 500-507.

¹⁹E.M. Creagh and L.A. O'Neill, TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity, *Trends Immunol*, 2006, **27**, 352-357.

²⁰J.T. Harty and V.P. Badovinac, Influence of effector molecules on the CD8(+) T cell response to infection, *Curr Opin Immunol*, 2002, **14**, 360-365.

²¹N. Čujić, K. Šavikin, T. Janković, D. Pljevljakušić, G. Zdunić and S. Ibrić, Optimization of polyphenols extraction from dried chokeberry using maceration as traditional technique, *Food Chem*, 2016, **194**, 135-42.

²²M.S. Butt, M.T. Sultan, M.S. Butt and J. Iqbal, Garlic: nature's protection against physiological threats, *Crit Rev Food Sci Nutr*, 2009, **49**, 538-551.

²³ C.S. Yu, K.C. Lai, J.S. Yang, J.H. Chiang, C.C. Lu, C.L. Wu, J.P. Lin, C.L. Liao, N.Y. Tang, W.G. Wood and J.G. Chung, Quercetin inhibited murine leukemia WEHI-3 cells in vivo and promoted immune response. *Phytother Res*, 2010, **24**, 163-168.

²⁴ T. Weichhart, G. Costantino, M. Poglitsch, M. Rosner, M. Zeyda, K. M. Stuhlmeier, T. Kolbe, T. M. Stulnig, W. H. Hörl, M. Hengstschläger, M. Müller, M.D. Säemann, The TSC-mTOR signaling pathway regulates the innate inflammatory response. *Immunity*, 2008, **29**, 565–577.

²⁵ E. Vergadi, E. Ieronymaki, K. Lyroni, K. Vaporidi and C. Tsatsanis, Akt Signaling Pathway in Macrophage Activation and M1/M2 Polarization. *J Immunol*, 2017, **198**, 1006-1014.

²⁶ T. Weichhart, M. Haidinger, K. Katholnig, C. Kopecky, M. Poglitsch, C. Lassnig, M. Rosner, G. J. Zlabinger, M. Hengstschläger, M. Müller, W.H. Hörl, and M.D. Säemann, Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells. *Blood*, 2011, **117**, 4273–4283.

²⁷ S.E.F. D'Orazio, Innate and Adaptive Immune Responses during *Listeria monocytogenes* Infection. *Microbiol Spectr*, 2019, **7**, 10.1128/microbiolspec.GPP3-0065-2019.

²⁸N. Yahfoufi, N. Alsadi, M. Jambi and C. Matar, The Immunomodulatory and Anti-Inflammatory Role of Polyphenols, *Nutrients*, 2018, **10**, 1618.

²⁹ S.H. Kim, S.Y. Park, Y.L. Park, D.S. Myung, J.S. Rew, Y.E. Joo, Chlorogenic acid suppresses lipopolysaccharide - induced nitric oxide and interleukin - 1 β expression by inhibiting JAK2/STAT3 activation in RAW264.7 cells. *Mol Med Rep*, 2017, **16**, 9224-9232.

³⁰ C.E. Varela, E. Fromentin, M. Roller, F. Villarreal and I. Ramirez-Sanchez, Effects of a natural extract of *Aronia Melanocarpa* berry on endothelial cell nitric oxide production. *J Food Biochem*, 2016, **40**, 404-410.

³¹ (J.H. Kim, C. Auger, I. Kurita, E. Anselm, L.O. Rivoarilala, H.J. Lee, K.W. Lee and V.B. Schini-Kerth, *Aronia melanocarpa* juice, a rich source of polyphenols, induces endothelium-dependent relaxations in porcine coronary arteries via the redox-sensitive activation of endothelial nitric oxide synthase. *Nitric Oxide*, 2013, **35**, 54-64.

³²S.P. Kim, E. Moon, S.H. Nam and M. Friedman, Composition of *Herba Pogostemonis* water extract and protection of infected mice against *Salmonella Typhimurium*-induced liver damage and mortality by stimulation of innate immune cells, *J Agric Food Chem*, 2012, **60**, 12122–12130.

³³A.M. Sullivan, J.G. Laba, J.A. Moore and T.D. Lee, Echinacea-induced macrophage activation, *Immunopharmacol Immunotoxicol*, 2008, **30**, 553–574.

³⁴ H. Kolodziej, O. Kayser, A.F. Kiderlen, H. Ito, T. Hatano, T. Yoshida and L.Y. Foo, Proanthocyanidins and related compounds: antileishmanial activity and modulatory effects on nitric oxide and tumor necrosis factor- α -release in the murine macrophage-like cell line RAW 264.7. *Biol Pharm Bull*, 2001, **24**, 1016-1021.

³⁵ R. Furuuchi, I. Shimizu, Y. Yoshida, Y. Hayashi, R. Ikegami, M. Suda, G. Katsuumi, T. Wakasugi, M. Nakao and T. Minamino, Boysenberry polyphenol inhibits endothelial dysfunction and improves vascular health. *PLoS One*, 2018, **13**, e0202051.

³⁶ G. López-López, L. Moreno, A. Cogolludo, M. Galisteo, M. Ibarra, J. Duarte, F. Lodi, J. Tamargo, F. Perez-Vizcaino, Nitric oxide (NO) scavenging and NO protecting effects of quercetin and their biological significance in vascular smooth muscle. *Mol Pharmacol*, 2004, **65**, 851-859.

³⁷ F. Aktan F, iNOS-mediated nitric oxide production and its regulation. *Life Sci*, 2004, **75**, 639-653.

³⁸ T. Kishimoto, The biology of interleukin-6. *Blood*, 1989, **74**, 1-10.

³⁹ W. Wongchana and T. Palaga, Direct regulation of interleukin-6 expression by Notch signaling in macrophages. *Cell Mol Immunol*, 2012, **9**, 155-162.

⁴⁰ G.D. Hurlbut, M.W. Kankel, R.J. Lake and S. Artavanis-Tsakonas, Crossing paths with Notch in the hyper-network. *Curr Opin Cell Biol*, 2007, **19**, 166-175.

⁴¹ C. Koorella, J.R. Nair, M.E. Murray, L.M. Carlson, S.K. Watkins and K.P. Lee, Novel regulation of CD80/CD86-induced phosphatidylinositol 3-kinase signaling by NOTCH1 protein in interleukin-6 and indoleamine 2,3-dioxygenase production by dendritic cells. *J Biol Chem*, 2014, **289**, 7747-7762.

⁴²V.P. Dwivedi, D. Bhattacharya, M. Singh, A. Bhaskar, S. Kumar, S. Fatima, P. Sobia, L.V. Kaer and G. Das, Allicin enhances antimicrobial activity of macrophages during *Mycobacterium tuberculosis* infection, *J Ethnopharmacol*, 2019, **243**, 111634.




Figure 1. The effect of CE pretreatment on *L. monocytogenes* infection in BALB/c mice. (A) Body weight change (%) during the days post infection in CE- and control-pretreated infected mice. The total number of mice per group was 8. (B) Bacterial burden in the spleen, observed through the number of colony forming units (CFU), and relative spleen weight (C), measured 48 h after the infection. The experiment was performed twice and the results of both experiments are shown. The total number of mice per group was from 10 to 12. * $p < 0.05$ represents a statistically significant difference vs. the control infection group.

85x98mm (300 x 300 DPI)




Figure 2. The effect of CE pretreatment on immune cells in the GALT. The proportion of immune cells was determined in PP of infected and CE-treated infected mice with *L. monocytogenes* 48 h after the infection.

The following immune cells were analyzed by flow cytometry: (A) CD11b⁺ macrophages, (B) CD11c⁺ dendritic cells, (C) CD8⁺ cytotoxic T lymphocytes and (D) CD4⁺ T helper cells. Representative dot plots are shown below the graphs. Ex vivo experiments were performed on 6 mice per group. Values of p are given where significant differences were found.

81x220mm (300 x 300 DPI)




Figure 3. The effect of CE pretreatment on immune cells in the spleen. The immune cell proportion was observed in the spleen of infected and CE-treated infected mice with *L. monocytogenes* 48 h after infection.

The following immune cells were analyzed by flow cytometry: (A) CD11b⁺ macrophages, (B) CD11c⁺ dendritic cells, (C) CD8⁺ cytotoxic T lymphocytes and (D) CD4⁺ T helper cells. Representative dot plots are shown on the right-hand side. Ex vivo experiments were performed on 6 mice per group. Values of p are given where significant differences were found.

83x240mm (300 x 300 DPI)




Figure 4. CE pretreatment effect on phagocytosis and ROS production. The proportion of phagocytic cells (%) and phagocytic activity, shown through the mean fluorescence intensity (MFI), were analyzed in the Peyer's patches (A) and the spleens (C) of CE or vehicle pretreated infected mice two days after *L. monocytogenes* infection. The proportion of ROS-producing cells and their MFI in Payer's patches (B) and spleens (D) of CE or vehicle pretreated infected mice two days after *L. monocytogenes* infection. Representative dot plots are shown on the right-hand side. Ex vivo experiments were performed on 6 mice per group. Values of p are given where significant differences were found.

137x206mm (300 x 300 DPI)




Figure 5. CE pretreatment effect on expression of myeloid cells co-stimulatory molecules. The proportion (%) of CD86 expressing macrophages (CD86+CD11b+ cells) and dendritic cells (CD86+CD11c+ cells) was determined in the PP (A), spleen (B) and MLN (C) of infected mice and CE-pretreated and infected mice 48 h after the infection. Representative dot plots are shown on the right-hand side. Ex vivo experiments were performed on 6 mice per group. Values of *p* are given where significant differences were found.

145x173mm (300 x 300 DPI)




Figure 6. CE effect on expression of pro-inflammatory mediators and transcription regulators. iNOS mRNA expression (A) and IL-6 mRNA expression (B) was determined in spleen cells of infected and CE-pretreated and infected mice 48 h after the infection with *L. monocytogenes*. Ex vivo experiments were performed on 6 mice per group. Peritoneal macrophages were in vitro treated with CE (25 $\mu\text{g}/\text{ml}$) and 24 h after the treatment NO production (C), iNOS expression (D) and IL-6 expression (E) were determined by RT-PCR. The level of I κ B phosphorylation (pI κ B) was normalized to total I κ B production in macrophages (F), while Notch1 production was normalized to the level of β -actin (determined by western blot) (G). Appropriate membrane images are presented. The experiment was performed in quadruplets. Values of *p* are given where significant differences were found.

175x282mm (300 x 300 DPI)

Table 1. The effect of CE on immune cell distribution in PP and spleen of healthy BALB/c mice.


Lymphoid tissue	Control (% cells)	CE-treated (% cells)
PP		
CD11b ⁺	1.2±0.7	1.6±0.8
CD11c ⁺	3.1±0.4	4.6±1.3*
CD8 ⁺	3.7±0.7	3.9±0.9
CD4 ⁺	22.6±3.6	21.5±2.4
Spleen		
CD11b ⁺	4.3±0.2	3.9±0.2
CD11c ⁺	2.5±0.3	2.5±0.1
CD8 ⁺	13.6±0.6	13.5±1.0
CD4 ⁺	22.8±1.7	20.0±1.3*

Healthy BALB/c mice were treated orally either with water (control) or with CE (50 mg/kg bw) for 7 days. The frequency of immune cells was determined in PP and spleen 24 h after the end of the treatment by flow cytometry. * $p < 0.05$ represents a statistically significant difference between CE-treated vs. the control group.

Table 2. The effect of CE pretreatment on the cells producing pro-inflammatory mediators against *L. monocytogenes* in spleen, PP and MLN.

Lymphoid tissue	Infected mice (% cells)	CE-pretreated +infected mice (% cells)
Spleen		
Granzyme ⁺	1.1±0.5	0.4±0.2
Perforin ⁺	1.1±0.2	1.9±0.6*
IFN-γ ⁺	2.5±0.9	2.2±0.9
PP		
Granzyme ⁺	0.4±0.1	0.4±0.1
Perforin ⁺	0.7±0.2	0.6±0.2
IFN-γ ⁺	0.2±0.0	0.2±0.1
MLN		
Granzyme ⁺	0.3±0.0	0.1±0.0
Perforin ⁺	0.4±0.1	0.3±0.1
IL-17 ⁺	0.4±0.0	0.3±0.1

Healthy BALB/c mice were treated orally either with water or with CE (50 mg/kg bw) for 7 days. 24 h after the last CE treatment, all mice were infected with *L. monocytogenes* (5×10^6 CFU in 100 μl of PBS). The frequency of immune cells was determined in lymphoid tissues of infected or CE-pretreated and infected mice 48 h after the infection by flow cytometry. * $p < 0.05$ represents a statistically significant difference between CE-pretreated and infected mice vs. the infected control group.



53x40mm (1000 x 1000 DPI)